Bordeaux

• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 4 2024-09-06 Resectable Gastric Cancer
• GuARD: GR1014 cutaneous gel Against Radiation Dermatitis Ended
  2023-508728-36-00 4 2024-07-26 Radiation-induced dermatitis (radiodermatitis)
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended
  2023-506823-28-00 4 2024-06-14 Adult patients with locally advanced/metastatic solid tumors
• EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended
  2023-509336-25-00 9 2024-06-12 Metastatic castration-resistant prostate cancer
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Pat … Ended
  2023-506976-28-00 9 2024-05-16 Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 7 2024-04-29 Unresectable Locally Advanced or Metastatic Cancer
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended
  2023-504630-22-00 7 2024-04-19 Non-Small Cell Lung Cancer
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos … Ended
  2023-506038-65-00 4 2024-04-15 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CA
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended
  2022-500823-61-00 7 2024-04-08 Advanced Solid Tumours
• FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC Ended
  2023-505145-93-00 7 2024-03-21 Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 Advanced or metastatic solid tumors

Showing 889–912 of 1,096 trials